KEMPHARM INC. DL-0001
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under P… Read more
KEMPHARM INC. DL-0001 (1GDA) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, KEMPHARM INC. DL-0001 (1GDA) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
KEMPHARM INC. DL-0001 - Net Assets Trend (None–None)
This chart illustrates how KEMPHARM INC. DL-0001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for KEMPHARM INC. DL-0001 (None–None)
The table below shows the annual net assets of KEMPHARM INC. DL-0001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to KEMPHARM INC. DL-0001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
KEMPHARM INC. DL-0001 Competitors by Market Cap
The table below lists competitors of KEMPHARM INC. DL-0001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cuscal Ltd
AU:CCL
|
$419.52 Million |
|
Bright Oceans Inter Telecom Corp
SHG:600289
|
$419.52 Million |
|
China Railway Special Cargo Logistics Co. Ltd.
SHE:001213
|
$419.62 Million |
|
Solomon Technology Corp
TW:2359
|
$419.65 Million |
|
AMG Advanced Metallurgical Group N.V.
PINK:AMVMF
|
$419.37 Million |
|
Lassonde Industries Inc
PINK:LSDAF
|
$419.32 Million |
|
Türk Telekomünikasyon Anonim Sirketi
PINK:TRKNF
|
$419.26 Million |
|
Community Healthcare Trust Inc
NYSE:CHCT
|
$419.21 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in KEMPHARM INC. DL-0001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares KEMPHARM INC. DL-0001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently KEMPHARM INC. DL-0001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares KEMPHARM INC. DL-0001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| KEMPHARM INC. DL-0001 (1GDA) | €- | N/A | N/A | $419.45 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |